SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Intarcia Therapeutics, Inc. Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions